Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 5
2018 5
2019 9
2020 4
2021 4
2022 10
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Antoniotti C, et al. Among authors: borelli b. Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27. Lancet Oncol. 2022. PMID: 35636444 Clinical Trial.
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Rossini D, et al. Among authors: borelli b. J Clin Oncol. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35666229 Free PMC article. Clinical Trial.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravezza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. Fucà G, et al. Among authors: borelli b. Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19. Br J Cancer. 2020. PMID: 32424148 Free PMC article.
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Rossini D, Germani MM, Lonardi S, Pietrantonio F, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, Randon G, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C. Rossini D, et al. Among authors: borelli b. Eur J Cancer. 2022 Jul;170:64-72. doi: 10.1016/j.ejca.2022.04.019. Epub 2022 May 17. Eur J Cancer. 2022. PMID: 35594613
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm.
Borelli B, Germani MM, Carullo M, Mattioni R, Manfredi B, Sainato A, Rossi P, Vagli P, Balestri R, Buccianti P, Morelli L, Antoniotti C, Cremolini C, Masi G, Moretto R. Borelli B, et al. Crit Rev Oncol Hematol. 2023 Jun;186:103985. doi: 10.1016/j.critrevonc.2023.103985. Epub 2023 Apr 13. Crit Rev Oncol Hematol. 2023. PMID: 37059274 Review.
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Borelli B, Conca V, Carullo M, Sainato A, Mattioni R, Manfredi B, Balestri R, Buccianti P, Morelli L, Rossi P, Vagli P, Prete AA, Luca F, Morano F, Donato SD, Salvatore L, Bengala C, Rossini D, Boni L, Antoniotti C, Cremolini C, Masi G, Moretto R. Borelli B, et al. Clin Colorectal Cancer. 2023 Sep;22(3):339-343.e3. doi: 10.1016/j.clcc.2023.06.002. Epub 2023 Jun 11. Clin Colorectal Cancer. 2023. PMID: 37429749 Clinical Trial.
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features.
Germani MM, Borelli B, Boraschi P, Antoniotti C, Ugolini C, Urbani L, Morelli L, Fontanini G, Masi G, Cremolini C, Moretto R. Germani MM, et al. Among authors: borelli b. Cancer Treat Rev. 2022 May;106:102382. doi: 10.1016/j.ctrv.2022.102382. Epub 2022 Mar 21. Cancer Treat Rev. 2022. PMID: 35334281 Review.
Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial).
Coccolini F, Mazzoni A, Cremonini C, Cobuccio L, Pucciarelli M, Vetere G, Borelli B, Strambi S, Musetti S, Miccoli M, Cremolini C; WIRES-T Study Group; Tartaglia D, Chiarugi M. Coccolini F, et al. Among authors: borelli b. Updates Surg. 2023 Sep;75(6):1579-1587. doi: 10.1007/s13304-023-01521-8. Epub 2023 May 9. Updates Surg. 2023. PMID: 37160552 Free PMC article.
45 results